Repligen Corp (RGEN)
145.93
-1.25
(-0.85%)
USD |
NASDAQ |
Sep 27, 16:00
145.96
+0.02
(+0.02%)
After-Hours: 20:00
Repligen SG&A Expense (Annual): 218.11M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
Date | Value |
---|---|
December 31, 2023 | 218.11M |
December 31, 2022 | 215.83M |
December 31, 2021 | 183.87M |
December 31, 2020 | 119.62M |
December 31, 2019 | 95.61M |
December 31, 2018 | 65.69M |
December 31, 2017 | 51.51M |
December 31, 2016 | 30.85M |
December 31, 2015 | 24.70M |
December 31, 2014 | 17.15M |
December 31, 2013 | 12.70M |
December 31, 2012 | 13.23M |
December 31, 2011 | 9.050M |
March 31, 2011 | 8.019M |
December 31, 2010 | 5.580M |
March 31, 2010 | 7.072M |
March 31, 2009 | 5.933M |
March 31, 2008 | 10.17M |
March 31, 2007 | 6.360M |
March 31, 2006 | 5.417M |
March 31, 2005 | 4.597M |
Date | Value |
---|---|
March 31, 2004 | 4.710M |
March 31, 2003 | 4.159M |
March 31, 2002 | 2.526M |
March 31, 2001 | 2.493M |
March 31, 2000 | 2.480M |
March 31, 1999 | 1.563M |
March 31, 1998 | 1.30M |
March 31, 1997 | 1.90M |
March 31, 1996 | 4.90M |
March 31, 1995 | 4.70M |
March 31, 1994 | 42.10M |
March 31, 1993 | 37.40M |
March 31, 1992 | 23.60M |
March 31, 1991 | 15.60M |
March 31, 1990 | 3.90M |
March 31, 1989 | 3.70M |
March 31, 1988 | 3.60M |
March 31, 1987 | 3.60M |
March 31, 1986 | 3.00M |
March 31, 1985 | 2.40M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
95.61M
Minimum
2019
218.11M
Maximum
2023
166.61M
Average
183.87M
Median
2021
SG&A Expense (Annual) Benchmarks
West Pharmaceutical Services Inc | 353.40M |
Perspective Therapeutics Inc | 21.06M |
Retractable Technologies Inc | 20.01M |
Xtant Medical Holdings Inc | 64.29M |
Catheter Precision Inc | 17.12M |